ISSN:
1569-8041
Keywords:
Mantle cell lymphonia
;
pbpc
;
therapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: Mantle cell lymphoma (MC) is not curable with conventionalchemotherapy. To improve the prognosis of patients with this disease, weprospectively studied an intensive sequential therapy consisting of theDexa-BEAM regimen (dexamethasone, BCNU, etoposide, ara-C, melphalan) followedby myeloablative therapy with autologous stem cell reinfusion. Patients and methods: Nine consecutive patients with stage III/IV MC wereincluded. Two had untreated disease, four were in first remission, whereasthree had more advanced disease. All patients underwent one to two cycles ofDexa-BEAM chemotherapy to reduce the tumor load and to mobilize peripheralblood progenitor cells (PBPC). Subsequently, patients were treated withhigh-dose radiochemotherapy followed by PBPC reinfusion and were prospectivelyanalyzed for residual disease by clinical methods as well as by PCRamplification clonal CDRIII rearrangements. Results: With an overall response rate of 100%, the initialDexa-BEAM cycles effectively reduced the tumor load. All patients proceededto high-dose therapy and subsequent stem cell rescue. Engraftment was prompt,and procedure-related deaths did not occur. With a median follow-up of 12(3–33) months post transplant, all patients are alive in continuingclinical and molecular remission. Conclusions: Sequential intensive therapy consisting of Dexa-BEAM andhigh-dose radiochemotherapy appears to be a highly effective treatment forpatients with MC. However, the data are still preliminary, and larger patientnumbers and a longer follow-up are required.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008251301319
Permalink
